Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rocatinlimab - Kyowa Kirin

Next Previous
X
Search
Drug Profile

Rocatinlimab - Kyowa Kirin

Alternative Names: AMG-451; KHK-4083

Latest Information Update: 26 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer Amgen; Kyowa Kirin
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Prurigo nodularis
  • Phase II Asthma
  • Suspended Ulcerative colitis

Most Recent Events

  • 04 Dec 2024 Amgen completes a phase III ROCKET-SHUTTLE trial in Atopic dermatitis (Combination therapy) in United Kingdom, USA, Turkey, Switzerland, Spain, Slovenia, Slovakia, Singapore, Romania, Puerto Rico, Poland, Netherlands, Japan, Japan, Japan, Malaysia, Italy, Hungary, Greece, Germany, France, China, Canada, Bulgaria, Belgium, Austria, Australia, Argentina (SC) (NCT05724199)
  • 14 Nov 2024 Amgen completes the phase III ROCKET-VOYAGER trial for Atopic dermatitis (In adults) (SC) in USA and Canada (NCT05899816)
  • 25 Sep 2024 Efficacy data from a phase III ROCKET Horizon trial in Atopic dermatitis released by Kyowa Kirin

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top